latest news releases from the newsroom
Allied Irish Banks, p.l.c.
Allied Irish Banks, P.L.C. Purchase of Own Shares
DUBLIN, Ireland, May 2, 2003 (PRIMEZONE) -- Allied Irish Banks, p.l.c. ("AIB") (NYSE:AIB) announces that on May 2, 2003, it purchased 620,000 of its ordinary shares, at an average price of (Eur)13.6596, to be held as treasury shares.
New Scandinavian Airlines Organization Agreed
STOCKHOLM, Sweden, May 02, 2003 (PRIMEZONE) -- The new Scandinavian Airlines (Other OTC:SASDF) organization was established today, May 2, 2003. The new organization is a feature of the improvement program (Plan C), which was presented in conjunction with the Group's Year-end Report earlier this spring. Plan C is based on the SAS Group's requirement that each operation within the Group achieve sustainable profitability and competitiveness.
Oneida Ltd. to Announce First Quarter Results
ONEIDA, N.Y., May 2, 2003 (PRIMEZONE) -- Oneida Ltd. (NYSE:OCQ) will release its results for the first quarter ended April 26, 2003 after the market closes on Tuesday, May 13, 2003. Management will host a conference call with analysts and investors on Wednesday, May 14, 2003 at 9:00 a.m. ET to discuss the company's results and operating performance for the first quarter of the fiscal year ending January 31, 2004. The conference call will be broadcast live over the Internet at www.oneida.com.
Options to Senior Executives in Volvo
GOTEBORG, Sweden, May 2, 2003 (PRIMEZONE) -- As announced previously, the Board of Directors of AB Volvo (Nasdaq:VOLVY) (Other OTC:VOLVF) (Other OTC:VOLAFK) has decided to again renew the personnel stock options program established in 2000 and through which senior executives in the Volvo Group are allotted options on B shares in AB Volvo. Allotment has now been made with regard to the 2002 program.
Amersham plc: Scientists and Industry Urge Regulators to Address Hurdles Facing Licensing of New Diagnostics for Alzheimer's Disease
NEW YORK, May 2, 2003 (PRIMEZONE) -- The Institute for the Study of Aging (ISOA) and Amersham (NYSE:AHM) (LSE:AHM) (OSE:AHM), a world leader in medical diagnostics and in life sciences, are hosting today a groundbreaking meeting to discuss the development of cutting-edge Positron Emission Tomography (PET) imaging products for the diagnosis of Alzheimer's disease. Leading experts on the molecular diagnosis of Alzheimer's disease from research institutions around the world gathered in New York to debate the clinical, economic and ethical implications of earlier and more accurate diagnosis of Alzheimer's disease, and the challenges of getting new diagnostics licensed. Participants also included senior executives from the pharmaceutical, biotechnology, diagnostic and insurance industries.